

FOSUN PHARMA 复星医药

上海復星醫藥（集團）股份有限公司

This announcement is made pursuant to Rule 13.09(2) and Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The following is the 2023 first quarterly report of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the “*公司*”, together with its subsidiaries, collectively the “*集團*”) (the “*報告*”) for the three months ended 31 March 2023 (the “*期間*”). The financial report therein is prepared in accordance with the PRC Accounting Standards for Business Enterprises and is unaudited.

By order of the Board

Shanghai, the People’s Republic of China

28 April 2023

* *公司* is a subsidiary of Fosun Pharmaceutical (Group) Co., Ltd.

(I) Major accounting information and financial indicators

Unit: Yuan Currency: RMB

	2022 Year	2021 Year		Change over 2021 Year
		2021 Year	2020 Year	
Operating revenue ¹	10,870,720,838.66	10,381,939,406.19	10,384,857,441.74	4.68
Net profit attributable to shareholders of the listed company ²	986,971,662.49	462,512,220.54	456,570,103.98	116.17
Net profit attributable to shareholders of the listed company after deducting extraordinary gain or loss ¹	919,320,722.64	800,945,771.83	800,945,771.83	14.78
Net cash flow generated from operating activities	873,244,036.36	865,594,441.10	855,611,632.32	2.06
Basic earnings per share (RMB/share)	0.37	0.18	0.18	105.56
Diluted earnings per share (RMB/share)	0.37	0.18	0.18	105.56
Return on weighted average net asset (%)	2.17	1.20	1.18	Increase by 0.99 percentage point

	2022 Year	2021 Year		Change over 2021 Year
		2021 Year	2020 Year	
Total assets	107,379,375,391.79	107,163,907,232.34	107,163,907,232.34	0.20
Equity attributable to shareholders of the listed company	45,393,160,518.35	44,582,457,512.55	44,582,457,512.55	1.82

¹ During the Reporting Period, the operating revenue and net profit attributable to shareholders of the listed company after deducting extraordinary gain or loss of the Group increased by 4.68% and 14.78% over the corresponding period of last year, respectively, which was mainly attributable to the combined impact of: (1) the growth in the revenue from new products and sub-new products, including Han Si Zhuang (serplulimab injection), Han Qu You (trastuzumab injection), Su Ke Xin (avatrombopag maleate tablets) and Jie Bei An (Azvudine tablets), with a further optimized revenue structure; (2) the period-on-period decline in the overseas sales contribution of non-proprietary public health protection supplies; and (3) the period-on-period decrease in the sales volume of Comirnaty (mRNA COVID-19 vaccine).

- 2 During the Reporting Period, extraordinary gain or loss of the Group amounted to RMB68 million, representing a period-on-period increase of RMB412 million, which was mainly attributable to the fact that the fair value losses of the financial assets such as BNTX shares held by the Group during the corresponding period of last year resulted in the extraordinary gain or loss of the Group for the corresponding period of last year of RMB-344 million, and such BNTX shares held by the Group were sold out in 2022.
- 3 During the Reporting Period, due to the business consolidations for enterprises under common control in 2022, the Group made retrospective adjustments to the comparative financial information in accordance with the PRC Accounting Standards for Business Enterprises.

(II) Extraordinary gain or loss items and amounts

Unit: Yuan Currency: RMB

	人民币元
Gain or loss on disposal of non-current assets	236,329,843.82
Government grants included in profit or loss for the current period exclude government grants closely related to the Company's normal operation, and entitled in fixed amounts or quantities on a continuous basis according to national standards	10,671,829.53
Profit or loss arising from changes in the fair value of holding financial assets held for trading, derivative financial assets, financial liabilities held for trading, derivative financial liabilities and investment income from disposal of financial assets held for trading, derivative financial assets, financial liabilities held for trading, derivative financial liabilities and other debt investments, except effective hedging business related to the Company's normal operations	7,253,498.29
Non-operating income and expenses other than those stated above	-42,375,260.14
Less: Effect of income tax	144,809,365.83
Impact on non-controlling interests (after tax)	-580,394.18
Total	67,650,939.85

(III) Changes in the principal accounting information and financial indicators and reasons for the changes

Net profit attributable to shareholders of the listed company	116.17	During the Reporting Period, both net profit attributable to shareholders of the listed company after deducting extraordinary gain or loss and extraordinary gain or loss of the Group achieved period-on-period growth. In particular, extraordinary gain or loss amounted to RMB68 million, representing a period-on-period increase of RMB412 million, which was mainly attributable to the fact that the fair value losses of the financial assets such as BNTX shares held by the Group during the corresponding period of last year resulted in the extraordinary gain or loss of the Group for the corresponding period of last year of RMB-344 million.
Basic earnings per share (RMB/share)	105.56	Same as above
Diluted earnings per share (RMB/share)	105.56	Same as above

Shareholder Name	Number of Shares	Share Class	
		Share Class	Number of Shares
Shanghai Fosun High Technology (Group) Company Limited* (上海復星高科技(集團)有限公司)	885,595,955 ¹	RMB ordinary shares	885,595,955
HKSCC NOMINEES LIMITED ²	551,358,830	Overseas listed foreign shares	551,358,830
China Securities Finance Corporation Limited* (中國證券金融股份有限公司)	38,736,079	RMB ordinary shares	38,736,079
Hong Kong Securities Clearing Company Limited ³	38,595,213	RMB ordinary shares	38,595,213
Bank of China Limited — China Merchants National Securities Biomedical Index Classified Securities Investment Fund* (招商國證生物醫藥指數分級證券投資基金)	20,387,178	RMB ordinary shares	20,387,178
National Social Security Fund Portfolio 113* (全國社保基金一一三組)	14,277,967	RMB ordinary shares	14,277,967
China Construction Bank Corporation — E Fund CSI 300 Medical and Healthcare Trading Open-End Index Securities Investment Fund* (易方達滬深300醫藥衛生交易 開放式指數證券投資基金)	12,002,495	RMB ordinary shares	12,002,495
Basic Pension Insurance Fund Portfolio 802* (基本養老保險基金八零二組)	10,286,517	RMB ordinary shares	10,286,517
Industrial and Commercial Bank of China — SSE Index 50 Trading Open-End Index Securities Investment Fund* (中國工商銀行—上證50交易 開放式指數證券投資基金)	9,217,608	RMB ordinary shares	9,217,608
Qiu Mingjing (邱明靜)	7,551,600	RMB ordinary shares	7,551,600
Description of the related relationship or concerted action of the above shareholders	The Company does not know whether any related relationship or concerted action exists between any of abovementioned shareholders of tradable shares.		
Status description of Top 10 shareholders and Top 10 unrestricted shareholders participating in securities margin trading and refinancing business (if any)	Qiu Mingjing (邱明靜) holds 7,551,600 shares, all of which are held through securities margin trading account.		

¹ Representing A shares only.

² HKSCC NOMINEES LIMITED, i.e. Hong Kong Securities Clearing Company Nominees Limited, is holding shares on behalf of multiple clients (shares held by it at the end of the Reporting Period includes an aggregate of 77,533,500 H shares of the Company held by Shanghai Fosun High Technology (Group) Company Limited* (上海復星高科技(集團)有限公司) and its controlling shareholder, Fosun International Limited, through it, representing approximately 2.90% of the total share capital of the Company as at the end of the Reporting Period).

³ Hong Kong Securities Clearing Company Limited is the nominee holder of the RMB ordinary shares under Shanghai-Hong Kong Stock Connect.

The investors are reminded to pay attention to other significant information concerning the Company's operations during the Reporting Period

In 2023, upholding the "4IN" strategy, the Group persisted in the development pattern of "innovation and transformation, integrated operation and steady development" and the mission of creating value for the shareholders, and continued to enhance self-R&D capacity and external cooperation, enrich its product pipelines, and strengthen its international layout.

In the first quarter of 2023, the operating revenue, net profit attributable to shareholders of the listed company and net profit attributable to shareholders of the listed company after deducting extraordinary gain or loss of the Group achieved growth. During the Reporting Period, the operating revenue of the Group amounted to RMB10,871 million, representing a period-on-period increase of 4.68%. Net profit attributable to shareholders of the listed company after deducting extraordinary gain or loss amounted to RMB919 million, representing a period-on-period increase of 14.78%. During the Reporting Period, the increase in the operating revenue and net profit attributable to shareholders of the listed company after deducting extraordinary gain or loss was mainly attributable to the combined impact of: (1) the growth in the revenue from new products and sub-new products, including Han Si Zhuang (serplulimab injection), Han Qu You (trastuzumab injection), Su Ke Xin (avatrombopag maleate tablets) and Jie Bei An (Azvudine tablets), with a further optimized revenue structure; (2) the period-on-period decline in the overseas sales contribution of non-proprietary public health protection supplies; and (3) the period-on-period decrease in the sales volume of Comirnaty (mRNA COVID-19 vaccine). In the first quarter of 2023, extraordinary gain or loss of the Group amounted to RMB68 million, representing a period-on-period increase of RMB412 million, which was mainly attributable to the fact that the fair value losses of the financial assets such as BNTX shares held by the Group during the corresponding period of last year resulted in the extraordinary gain or loss of the Group for the corresponding period of last year of RMB-344 million, and such BNTX shares held by the Group were sold out in 2022. Due to the period-on-period increase in extraordinary gain or loss, the net profit attributable to shareholders of the listed company during the Reporting Period increased by 116.17% over the corresponding period of last year. During the Reporting Period, net cash flow generated from operating activities of the Group amounted to RMB873 million, representing a period-on-period increase of 2.06%.

Since 2023, the Group's main operations and product R&D progress are as follows:

Continued to promote the development and launch of innovative products

- (i) A number of innovative products/indications have been approved for launch: During the Reporting Period, Han Si Zhuang (serplulimab injection), the first self-developed biopharmaceutical innovative drug of the Group, has been approved for an additional indication, i.e. extensive-stage small cell lung cancer (ES-SCLC), indicating that Han Si Zhuang has become the world's first monoclonal antibody drug targeting PD-1 approved for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC), and its marketing authorization application (MAA) in the EU has also been accepted. Keverprazan Hydrochloride tablets (trade name: Bei Wen (倍穩)), the first potassium ion competitive acid blocker (P-CAB) independently developed in China, jointly developed by the Group and Jiangsu Carephar Pharmaceutical Co., Ltd.* (江蘇柯菲平醫藥股份有限公司), and exclusively commercialized by the Group, was approved for launch in Chinese mainland (excluding Hong Kong, Macau and Taiwan, China, the same below) for the treatment of duodenal ulcer (DU) and reflux esophagitis (RE).
- (ii) A number of products independently developed and licensed-in have successively entered the critical clinical/approval stage: During the Reporting Period, independently developed by the Group, the first patient dosing in the phase III of the international multi-center clinical study of Han Si Zhuang (serplulimab injection) in combination with chemotherapy and concurrent radiotherapy for the treatment of limited-stage small cell lung cancer (LS-SCLC) has been completed in the United States; the U.S. biologics license application (BLA) for Han Qu You (trastuzumab injection), the first domestic monoclonal antibody biosimilar approved by both China and the European Union, has been accepted by the U.S. FDA, which is expected to become the first domestic monoclonal antibody biosimilar approved in China, the European Union and the United States, further covering the mainstream biopharmaceutical markets in Europe and the United States; the enrollment of the phase III clinical trial in Chinese mainland of 13-valent pneumococcal conjugate vaccines (multivalent combinations) has been completed in April 2023; FCN-159 for the treatment of histiocytic tumors has been included in the breakthrough therapy drug program by the National Medical Products Administration of the People's Republic of China (the “NMPA”) in April 2023. In addition, licensed-in by the Group, the phase III clinical study of FS-1502 (recombinant HER2 humanized monoclonal antibody-monomethyl auristatin F conjugate for injection) for the treatment of HER2-positive unresectable locally advanced or metastatic breast cancer has been initiated in Chinese mainland during the Reporting Period; HLX208 (BRAF V600E inhibitor) for the treatment of BRAF V600E mutated langerhans cell histiocytosis (LCH) in adults and Erdheim-Chester disease (ECD) has been included in the breakthrough therapy drug program by the NMPA in April 2023; the new drug

application in Chinese mainland of RT002 (DaxibotulinumtoxinA) for the temporary improvement of moderate to severe glabellar lines in adults caused by corrugator supercilii and/or procerus muscle activity has been accepted in April 2023.

- (iii) Continuous establishment of production systems in line with the domestic and international requirements: During the Reporting Period, Fosun Antejin (Chengdu) Biomedical Co., Ltd.* (復星安特金(成都)生物製藥有限公司), a subsidiary, received the Drug Manufacturing Certificate (《藥 生產許可證》), laying a foundation for its subsequent commercial production of pipeline vaccine products.

Investment and BD progress

During the Reporting Period, Sisram Medical Ltd (“西思拉姆 醫學器械”), a subsidiary, entered into an agreement with PhotonMed International Limited, based on which Sisram Medical proposed to control the brand and channels of “Alma” through merger and acquisition of assets, so as to achieve a direct sales layout in the Chinese market for the energy source medical beauty equipment business and enhance the brand awareness on the user end.

In April 2023, Gland Pharma Limited, a subsidiary, completed the acquisition of Cenexi (i.e. Phixen, société par actions simplifiée), a European CDMO company, so as to strategically establish its CDMO business presence in the European market and build up local manufacturing capabilities in Europe. In addition, Shanghai Henlius Biotech, Inc.* (上海復宏漢霖生物技術股份有限公司), a subsidiary, entered into a licensing and supply agreement with Boston Oncology, LLC (“波士頓腫瘤藥業”), granting the exclusive development a xcl549.2ortinIa7(Tj/F621Tfl-24.up

(Continued)
31 December 2023

Unit: Yuan Currency: RMB Type of audit: Unaudited

Short-term loans	14,012,819,200.10	11,931,537,165.93
Bills payable	832,042,279.22	857,879,140.38
Trade payable	5,805,946,950.42	5,426,161,923.19
Contract liabilities	1,073,749,398.44	1,544,762,576.49
Wages payable	1,135,746,685.21	1,640,222,238.38
Tax payable	872,053,638.79	929,835,697.13
Other payables	4,962,627,508.31	5,353,265,590.30
Including: Interests payable	—	—
Dividends payable	33,579,965.75	34,443,965.75
Non-current liabilities due within one year	3,678,048,083.99	5,471,331,900.27
Other current liabilities	95,046,744.44	143,073,225.18
Total current liabilities	32,468,080,488.92	33,298,069,457.25
Long-term loans	11,851,681,250.08	11,600,437,131.66
Bonds payable	499,547,964.85	499,431,152.21
Lease liabilities	737,928,680.29	744,992,648.18
Long-term payables	346,629,665.70	337,819,540.68
Long-term wages payable	11,948,531.78	42,068,155.09
Deferred income	591,353,848.74	632,432,895.82
Deferred tax liabilities	3,340,460,904.44	3,362,940,237.33
Other non-current liabilities	2,484,029,434.13	2,536,806,400.77
Total non-current liabilities	19,863,580,280.01	19,756,928,161.74
Total liabilities	52,331,660,768.93	53,054,997,618.99
Share capital	2,672,156,611.00	2,672,156,611.00
Capital reserve	16,968,469,974.41	16,992,138,223.00
Less: Treasury shares	53,254,806.00	53,254,806.00
Other comprehensive income	-1,384,106,481.65	-1,198,363,947.81
Surplus reserve	2,952,929,442.20	2,952,929,442.20
Unappropriated profit	24,236,965,778.39	23,216,851,990.16
Total equity attributable to the owners (or shareholders) of the parent company	45,393,160,518.35	44,582,457,512.55
Non-controlling interests	9,654,554,104.51	9,526,452,100.80
Total owners' equity (or shareholders' equity)	55,047,714,622.86	54,108,909,613.35
Total liabilities and owners' equity (or shareholders' equity)	107,379,375,391.79	107,163,907,232.34

(Continued)

2023

Unit: Yuan Currency: RMB Type of audit: Unaudited

VI. Other comprehensive income, net of tax	-183,486,478.67	-268,577,673.95
(I) Other comprehensive income attributable to the owners of the parent company, net of tax	-152,600,408.10	-187,109,896.22
1. Other comprehensive income not reclassified subsequently to profit or loss	1,964,833.34	-36,885,845.14
(1) Other comprehensive income using the equity method that will not be reclassified to profit or loss	—	-33,142,125.74
(2) Change in the fair value of other equity instrument investments	1,964,833.34	-3,743,719.40
2. Other comprehensive income reclassified subsequently to profit or loss	-154,565,241.44	-150,224,051.08
(1) Other comprehensive income using the equity method that will be reclassified to profit or loss	-82,067,375.10	-75,363,594.93
(2) Exchange differences on translation of foreign currency financial statements	-72,497,866.34	-74,860,456.15
(II) Other comprehensive income attributable to non-controlling interests, net of tax	-30,886,070.57	-81,467,777.73
VII. Total comprehensive income	930,767,631.49	365,586,120.33
(I) Total comprehensive income attributable to the owners of the parent company	834,371,254.39	269,460,207.76
(II) Total comprehensive income attributable to non-controlling interests	96,396,377.10	96,125,912.57
VIII. Earnings per share:		
(I) Basic earnings per share (yuan/share)	0.37	0.18
(II) Diluted earnings per share (yuan/share)	0.37	0.18

Due to the business consolidations for enterprises under common control in 2022, the Group made retrospective adjustments to the comparative financial information in accordance with the PRC Accounting Standards for Business Enterprises. The net profit realized by the consolidated parties in the corresponding period of last year amounted to RMB-10,121,514.91.

2023

Unit: Yuan Currency: RMB Type of audit: Unaudited

Cash received from sale of goods and rendering of services	10,695,529,511.42	10,407,617,624.32
Refund of taxes and levies	83,838,265.49	127,885,045.45
Other cash received relating to operating activities	1,086,143,315.26	804,461,008.36
Sub-total of cash inflow generated from operating activities	11,865,511,092.17	11,339,963,678.13
Cash paid for purchasing goods and receiving services	4,489,769,536.26	5,247,023,267.11
Cash paid to and on behalf of employees	2,842,577,879.20	2,471,363,105.93
Cash paid for all types of taxes	778,299,147.21	564,229,885.67
Other cash paid relating to operating activities	2,881,620,493.14	2,201,735,787.10
Sub-total of cash outflow generated from operating activities	10,992,267,055.81	10,484,352,045.81
Net cash flow generated from operating activities	873,244,036.36	855,611,632.32
Cash received from disposal of investments	496,377,082.92	1,116,526,050.66
Cash received from returns on investments	104,941,318.80	16,027,091.23
Net cash received from disposal of fixed assets, intangible assets and other long-term assets	2,259,612.97	52,115,314.87
Net cash received from disposal of subsidiaries and other operating segments	—	385,273,200.43
Other cash received relating to investing activities	1,119,124,084.42	164,483,805.89
Sub-total of cash inflow generated from investing activities	1,722,702,099.11	1,734,425,463.08
Cash paid for acquisition of fixed assets, intangible assets and other long-term assets	1,703,104,220.00	1,499,031,485.85
Cash paid for investments	84,545,733.20	283,399,689.70
Net cash paid for acquisition of subsidiaries and other operating segments	47,589,200.00	459,451,147.70
Other cash paid relating to investing activities	24,638,334.95	962,273,659.60
Sub-total of cash outflow generated from investing activities	1,859,877,488.15	3,204,155,982.85
Net cash flow generated from investing activities	-137,175,389.04	-1,469,730,519.77

(Continued)
2023

Unit: Yuan Currency: RMB Type of audit: Unaudited

Cash received from capital contribution	17,225,100.00	23,743,405.82
Including: Cash received by subsidiaries from investments of non- controlling interests	17,225,100.00	23,743,405.82
Cash received from borrowings	6,883,841,990.77	7,507,780,854.35
Other cash received relating to financing activities	159,047,273.55	356,007,995.59
Sub-total of cash inflow generated from financing activities	7,060,114,364.32	7,887,532,255.76
Cash paid for debts settlement	6,254,317,689.90	4,897,780,791.20
Cash paid for the distribution of dividends, profits or interests	325,842,605.08	230,882,008.15
Including: Dividends and profits paid by subsidiaries to non-controlling interests	864,000.00	—
Other cash paid relating to financing activities	197,982,914.89	1,205,558,409.32
Sub-total of cash outflow generated from financing activities	6,778,143,209.87	6,334,221,208.67
Net cash flow generated from financing activities	281,971,154.45	1,553,311,047.09
	-67,365,428.91	-47,005,915.34
	950,674,372.86	892,186,244.30
Plus: Opening balance of cash and cash equivalents	11,170,066,988.55	6,459,717,065.10
	12,120,741,361.41	7,351,903,309.40

(Continued)
31 December, 2023

(Continued)

Unit: Yuan Currency: RMB Type of audit: Unaudited

	2023	2022
Share capital	2,672,156,611.00	2,672,156,611.00
Capital reserve	18,746,542,967.33	18,750,823,068.12
Less: Treasury shares	53,254,806.00	53,254,806.00
Other comprehensive income	-258,554,990.68	-157,364,697.37
Surplus reserve	1,336,078,305.50	1,336,078,305.50
Unappropriated profit	12,025,666,993.91	11,687,129,212.92
Total owners' equity (or shareholders' equity)	34,468,635,081.06	34,235,567,694.17
Total liabilities and owners' equity (or shareholders' equity)	48,476,339,825.05	49,535,569,590.56

2023

Unit: Yuan Currency: RMB Type of audit: Unaudited

I. Operating revenue	1,038,290.75	697,698.11
Less: Tax and surcharges	377.47	106,985.60
General and administrative expenses	74,795,370.25	49,759,769.63
Research and development expenses	10,691,020.30	—
Finance costs	54,186,952.72	90,746,263.51
Including: Interest expenses	94,055,739.02	116,783,686.52
Interest income	35,109,005.24	25,962,562.39
Plus: Investment income (“-” indicating loss)	548,992,362.94	568,141,870.42
Including: Investment income from associates and joint ventures	406,541,441.65	425,690,949.14
Gains from disposal of assets (“-” indicating loss)	60,295.07	—
II. Operating profit (“-” indicating loss)	410,417,228.02	428,226,549.79
Plus: Non-operating revenue	—	—
Less: Non-operating expenses	332,800.00	2,600,000.00
III. Total profit (“-” indicating total loss)	410,084,428.02	425,626,549.79
Less: Income tax expenses	104,688,772.77	—
IV. Net profit (“-” indicating net loss)	305,395,655.25	425,626,549.79
(I) Net profit from continuing operation (“-” indicating net loss)	305,395,655.25	425,626,549.79
(II) Net profit from discontinued operation (“-” indicating net loss)	—	—
V. Other comprehensive income, net of tax	-68,048,167.57	-106,699,786.41
(I) Other comprehensive income not reclassified subsequently to profit or loss	—	-33,142,125.74
1. Other comprehensive income using the equity method that will not be reclassified to profit or loss	—	-33,142,125.74
(II) Other comprehensive income reclassified subsequently to profit or loss	-68,048,167.57	-73,557,660.67
1. Other comprehensive income using the equity method that will be reclassified to profit or loss	-68,048,167.57	-73,557,660.67
VI. Total comprehensive income	237,347,487.68	318,926,763.38
VII. Earnings per share:		
(I) Basic earnings per share (yuan/share)	N/A	N/A
(II) Diluted earnings per share (yuan/share)	N/A	N/A

2023

Unit: Yuan Currency: RMB Type of audit: Unaudited

Cash received from sale of goods and rendering of services	440,800.00	—
Other cash received relating to operating activities	452,607,853.50	4,476,158.75
Sub-total of cash inflow generated from operating activities	453,048,653.50	4,476,158.75
Cash paid to and on behalf of employees	57,716,527.91	51,126,039.23
Cash paid for all types of taxes	110,785.64	117,772.33
Other cash paid relating to operating activities	23,864,251.77	417,954,741.65
Sub-total of cash outflow generated from operating activities	81,691,565.32	469,198,553.21
Net cash flow generated from operating activities	371,357,088.18	-464,722,394.46
Cash received from disposal of investments	—	2,277,299.97
Sub-total of cash inflow generated from investing activities	—	2,277,299.97
Cash paid for acquisition of fixed assets, intangible assets and other long-term assets	1,987,268.76	144,260.00
Cash paid for investments	71,589,200.00	36,775,000.00
Sub-total of cash outflow generated from investing activities	73,576,468.76	36,919,260.00
Net cash flow generated from investing activities	-73,576,468.76	-34,641,960.03
Cash received from borrowings	2,311,482,507.90	2,195,000,000.00
Other cash received relating to financing activities	4,400,378,820.50	3,436,187,279.18
Sub-total of cash inflow generated from financing activities	6,711,861,328.40	5,631,187,279.18
Cash paid for debts settlement	3,277,718,800.00	2,420,900,000.00
Cash paid for the distribution of dividends, profits or interest	163,409,748.60	154,758,263.65
Other cash paid relating to financing activities	3,093,059,391.33	2,263,687,913.71
Sub-total of cash outflow generated from financing activities	6,534,187,939.93	4,839,346,177.36
Net cash flow generated from financing activities	177,673,388.47	791,841,101.82
	-425,858.34	62,538.26
	475,028,149.55	292,539,285.59
Plus: Opening balance of cash and cash equivalents	722,772,306.06	77,536,013.63
	1,197,800,455.61	370,075,299.22

Not applicable

Not applicable

By order of the Board

Signature of the Chairman of the Board

Shanghai, the People's Republic of China

28 April 2023

*